CHE Chemed (CHE) Q4 FY25 earnings call
Chemed reported a challenging Q4 FY25, missing expectations due to specific operational headwinds at both VITAS and Roto-Rooter. VITAS successfully mitigated its Florida Medicare Cap risk by increasing short-stay admissions, which temporarily compressed revenue and EBITDA margins. Roto-Rooter faced revenue declines and margin pressure from increased water restoration write-offs and higher marketing costs for lead generation. Management views 2026 as a transition year, with financial results expected to build in the second half as strategic initiatives take hold.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
CHE operating KPIs by quarter
| KPI | This call Dec 2025 Q4 FY25 | Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|
| Average daily census VITAS | 22.462KIn the fourth quarter of 2025, our average daily census was 22,462 patients, an increase of 1.3%.Source: earnings call transcript | 23.687KIn the second quarter of 2026, our average daily census was 23,687 patients.Source: earnings call transcript | +5.5% |
| Average length of stay VITAS | 115.1Our average length of stay in the quarter was 115.1 days.Source: earnings call transcript | 101.2Our average length of stay in the quarter was 101.2 days.Source: earnings call transcript | -12.1% |
| Median length of stay VITAS | 17Our median length of stay was 17 days in the fourth quarter of 2025, 1 day less than the median in the fourth quarter of 2024.Source: earnings call transcript | 16Our median length of stay was 16 days in the second quarter of 2026, a decline of 4 days from the second quarter of 2025.Source: earnings call transcript | -5.9% |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.